Chiara Ballerini

Chiara Ballerini

Auto-generated profile, based on publicly available information

Chiara Ballerini

Department of NEUROFARBA, University of Florence, Florence, Italy

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2026 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
EPEmilio Portaccio
Emilio Portaccio
MAMaria Grazia Aprea
Maria Grazia Aprea
EMErmelinda De Meo
Ermelinda De Meo
MBMatteo Betti
Matteo Betti
IAIlaria Addazio
Ilaria Addazio
MAMaria Pia Amato
Maria Pia Amato
Background In multiple sclerosis (MS), disability accrual can arise from relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA). While genetic variants associated with increased MS severity have been identified, little is known on apolipoprotein E (ApoE) gene. This study aims to investigate the impact of the ApoE ε4 allele (ApoE4) on disability accrual in relapsing MS patients. Methods Patients with relapsing MS, aged >18 years, consecutively referred to the MS centre at the University of Florence, Italy, were recruited (n=160). Patients were classified as ApoE4 carriers and non-carriers. The first confirmed disability accrual (CDA) was defined as ≥24-week confirmed disability increase from roving baseline. PIRA was defined as a CDA with absence of relapses <90 days before and <30 days after the onset of disability accrual and confirmation event. The association between APOE4 and type of first CDA was assessed using multivariable Cox proportional hazard regressions. Results After a follow-up of 12.3±6.3 years, a first CDA occurred in 97 patients (60.6%). PIRA accounted for 58 (59.8%) CDA events in the whole sample and for 7 out of 18 (38.9%) CDA events in APOE4 non-carriers (p=0.045). Indeed, RAW was associated with ApoE4 in the whole sample (HR=3.33, 95% CI 1.53 to 7.27, p=0.002) and in patients with relapses during follow-up (HR=3.60, 95% CI 1.62 to 8.02, p=0.002). Interpretation Our study underscores the importance of genetic factors such as ApoE4 in MS pathogenesis. The identification of genetic markers associated with specific patterns of disability accrual could unveil mechanisms of damage accumulation and provide new therapeutic targets.

8 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
CBChiara Ballerini
Chiara Ballerini
NCNiccolò Cardente
Niccolò Cardente
MAMaria Francesca Abbate
Maria Francesca Abbate
KQKhang Lê Quý
Khang Lê Quý
NRNatalia Rincon
Natalia Rincon
VGVictor Greiff
Victor Greiff
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) in which B cells play a critical role. While B-cell receptor (BCR) sequencing studies in MS are increasing, progress in understanding MS-associated BCR repertoire features and convergent patterns across patients has been limited by small cohorts, heterogeneous experimental methodologies, and fragmented data storage. To overcome these challenges, we developed the MS-BCR-Database, the first publicly accessible and uniformly processed collection of human MS BCR sequencing datasets. We harmonized raw BCR-sequencing data into an AIRR-compliant database incorporating clinical and technical metadata, enabling coherent cross-study analyses. Using this resource, we identified putative disease-associated BCR-sequence features, including CNS-biased V-gene usage, marked oligoclonal expansion in cerebrospinal fluid, and convergent clonotype clusters shared exclusively among MS patients. Integration with antigen-annotated BCR databases revealed matches to antibodies recognizing both viral antigens, including Epstein-Barr virus, and CNS self-proteins. The MS-BCR-Database provides a scalable foundation for mechanistic discovery and biomarker development in MS, while establishing a broadly applicable resource for integrative analyses of BCR repertoires.